
858 Therapeutics: Innovating small molecule drugs for oncology, focusing on RNA regulation and immune response.
Founded by a veteran team with a successful track record in pharma and biotech drug discovery, 858 Therapeutics is a biotechnology company focused on developing small molecule drugs targeting novel therapeutic areas. Their core mission is to innovate treatments in oncology, neuroscience, and cardiovascular disease by focusing on synthetic lethality, innate immunity, and RNA modulation. The company aims to address unmet medical needs through cutting-edge drug discovery and development.
Notable affiliated individuals include experienced leaders from the pharmaceutical and biotech industries. 858 Therapeutics has garnered attention for its pioneering approach to targeting RNA regulation and the immune response in cancer therapy. Their key achievements include advancing a robust pipeline of drug candidates and securing strategic partnerships. The overall impact of 858 Therapeutics lies in its potential to transform treatment paradigms for serious diseases, offering new hope to patients worldwide.

Remix Therapeutics

Expansion Therapeutics
expansionrx.com

ReviR Therapeutics
revirtx.com

Synnovation Therapeutics
synnovationtx.com
Rnav8 Bio

OncXerna Therapeutics
oncxerna.com

Rgenta Therapeutics
rgentatx.com

Arrakis Therapeutics
arrakistx.com

Altay Therapeutics

Rnaderm Therapeutics

Nextrna Therapeutics

Palm Therapeutics

Celsius Therapeutics
celsiustx.com

BlossomHill Therapeutics
bhtherapeutics.com

Exo Therapeutics
Companies similar to 858 Therapeutics include Remix Therapeutics, Expansion Therapeutics, ReviR Therapeutics and Synnovation Therapeutics.
858 Therapeutics was founded in 2019.
858 Therapeutics' headquarters is located in San Diego, CA, US.
858 Therapeutics' most recent funding round was for $60M (USD) in September 2021.
As of Sep 21, 2021, 858 Therapeutics has raised a total of $80.1M (USD).
858 Therapeutics has 27 employees as of Feb 5, 2024.